Safety and Performance of Agilik in CP
- Conditions
- Cerebral Palsy
- Interventions
- Device: AgilikOther: standard care
- Registration Number
- NCT05746871
- Lead Sponsor
- IRCCS Eugenio Medea
- Brief Summary
The purpose of this post market study is to demonstrate the safety and performance of a powered extension assist (EA) knee ankle foot orthosis (KAFO), or EA-KAFO, in individuals with knee extension deficiency due to cerebral palsy (CP). The EA-KAFO tested in this investigation, whose commercial name is Agilik™, is registered as a Class 1 medical device in the European (EU) Medical Device Regulation (MDR) and with the United States (US) Food and Drugs Administration (FDA). The study will take place in Astrolab at the Istituto Scientifico E. MEDEA - La Nostra Famiglia (IRCCS Medea hereafter). The duration of the investigation will be 36 months. The duration of the study for a single subject will be approximately 10 weeks.
The primary purpose of this study is to demonstrate the safety and performance of a powered extension assist knee ankle foot orthosis (Agilik) in individuals with knee extension deficiency due to cerebral palsy. The focus is on the improvement of anti-gravity knee extension during stance in patients with CP with crouch gait. Therefore, the primary aim is to compare the knee and range of motion (ROM) at baseline and after 10 sessions of Agilik training while wearing Agilik itself. Secondary aim is to compare knee ROM before and after the training with Agilik without wearing Agilik.
The changes in lower extremity functions, kinematics and muscle activity during walking with Agilik compared to baseline conditions will be examined. Furthermore, the performance of Agilik during uphill and downhill walking over the GRAIL platform will be investigated.
Hypotheses when using Agilik:
* Improve knee extension during stance and swing gait phases
* Increase step length, walking distance and speed
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 20
- Provision of signed and dated informed consent form.
- Stated willingness to comply with all study procedures and availability for the duration of the study, or alternatively, ability to do so based on parent report and physician observation during history and physical examination.
- Age between 5 and 17
- Maximum weight of 70 Kg
- Volunteer who have a gait pathology involving the knee joint, from a diagnosis of CP
- Knee flexion retraction assessed in supine position by less than 10°. Hamstring contracture as assessed by straight leg raising test does not limit ability to participate in the study.
- Subjects must not have had a tibio-tarsal arthrodesis. In addition, they must have at least 10° of passive dorsi-flexion of the ankle.
- Able to walk at least 3 m without stopping with or without a walking aid.
- Able to understand and follow simple directions based on parent report and physician observation during history and physical examination.
- GMFCS level I, II and III
- MAS score ≤ 2
- Any neurological, musculoskeletal or cardiorespiratory injury, health condition, or diagnosis other than cerebral palsy that would affect the ability to walk as directed for short periods of time.
- A history of uncontrolled seizure in the past year
- Severe spasticity
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description GroupA_Agilik first Agilik This arm will be assessed at T0, then it will receive the intervention with Agilik (10 training sessions in 5 weeks) and will perform T1 evaluations, and then it will repeat the evaluations after other 5 weeks (T2) during which they performed they standard care GroupA_Agilik first standard care This arm will be assessed at T0, then it will receive the intervention with Agilik (10 training sessions in 5 weeks) and will perform T1 evaluations, and then it will repeat the evaluations after other 5 weeks (T2) during which they performed they standard care GroupB_standard care first standard care This arm will be assessed at T0, then it will continue with their standard care and will perform T1 evaluation after 5 weeks, and then it will receive the intervention with Agilik (10 training sessions in 5 weeks) and the final evaluation (T2) GroupB_standard care first Agilik This arm will be assessed at T0, then it will continue with their standard care and will perform T1 evaluation after 5 weeks, and then it will receive the intervention with Agilik (10 training sessions in 5 weeks) and the final evaluation (T2)
- Primary Outcome Measures
Name Time Method change of range of motion of the knee overground 6 weeks the range of motion of the knee will be measured by means of BTS Bioengineering S.p.A. optoelectronic system during the overground gait analysis assessment with Agilik
change in gait speed 6 weeks the gait speed will be measured by means of the 10 meters walking test (10mWT) with Agilik
satisfaction using Agilik 6 weeks the children's satisfaction with Agilik will be evaluated with the Quebec User Evaluation of Satisfaction adapted to children (QUEST 2.1).
change of range of motion of the knee uphill/downhill 6 weeks the range of motion of the knee will be measured by means of the GRAILoptoelectronic system that is equipped with a motion platform and that will simulate uphill and downhill walking while performing gait analysis assessment with Agilik
change in centre of mass oscillations 6 weeks Centre of mass (COM) oscillations will be measured during 1 minute of standing by means of the G-Sensor, a wearable three axial accelerometer and gyroscope
change in endurance 6 weeks The endurance will be measured by means of the 6 minute walking test (6MWT) with Agilik
change in spasticity 6 weeks The level of spasticity in the lower limbs will be measured by means of the Ashworth scale (MAS level, Modified Ashworth scale level) with Agilik
change in muscle lengths 6 weeks Joint and muscle lengths examination will be performed manually
change in centre of pressure oscillations 6 weeks Centre of pressure (COP) oscillations will be assessed by means of the force plates embedded in the GRAIL system, during 1 minute of still standing
- Secondary Outcome Measures
Name Time Method change in centre of pressure oscillations without Agilik 6 weeks Centre of pressure (COP) oscillations will be assessed by means of the force plates embedded in the GRAIL system, during 1 minute of still standing without Agilik
change of range of motion of the knee overground without Agilik 6 weeks the range of motion of the knee will be measured by means of BTS Bioengineering S.p.A. optoelectronic system during the overground gait analysis assessment without Agilik
change of range of motion of the knee uphill/downhill without Agilik 6 weeks the range of motion of the knee will be measured by means of the GRAILoptoelectronic system that is equipped with a motion platform and that will simulate uphill and downhill walking while performing gait analysis assessment without Agilik
change in endurance without Agilik 6 weeks The endurance will be measured by means of the 6 minute walking test (6MWT) without Agilik
change in gait speed without Agilik 6 weeks the gait speed will be measured by means of the 10 meters walking test (10mWT) without Agilik
change in centre of mass oscillations without Agilik 6 weeks Centre of mass (COM) oscillations will be measured during 1 minute of standing without Agilik by means of the G-Sensor, a wearable three axial accelerometer and gyroscope
Trial Locations
- Locations (1)
IRCCS Medea
🇮🇹Bosisio Parini, Italy